PTPavel E. Tulin

Pavel E. Tulin

*This is an algorithmically generated author record based on publicly available information.

Pavel E. Tulin has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PET/CT with 68Ga-FAPI and 18F-FDG in the Detection of Distant Metastases of Gastric Cancer

    by E. V. Belkin, P. E. Tulin, A. M. Badeyan, O. B. Abu‑Khaidar, V. V. Solomyanyy, A. V. Filimonov

    Purpose : To determine the diagnostic effectiveness of PET/CT with 68 Ga-FAPI in the detection and staging of metastases in patients with gastric cancer. Material and methods : The study included 57 patients with histologically confirmed gastric cancer. All patients underwent PET/CT with 68 Ga-FAPI and PET/CT with 18 F-FDG. The diagnostic accuracy of the methods was compared based on sensitivity and specificity parameters in detecting distant metastatic lesions. Data assessment was conducted based on histologically verified disease and clinical follow-up data. Results : 57 patients underwent both 68 Ga-FAPI PET/CT and 18 F-FDG PET/CT. In 5 patients (8.7 %), the treatment plan was changed from radical to palliative based on the 68Ga-FAPI PET/CT results. 68 Ga-FAPI PET/CT detected distant metastases in 29 patients (50.8 %), while with 18 F-FDG, distant metastases were detected in 18 patients (31.5 %). The sensitivity of 68 Ga-FAPI PET/CT in detecting distant metastases was 100 %, with a specificity of 85.7 %, whereas for 18 F-FDG, these values were 62 % and 90 %, respectively. Conclusion : PET/CT with 68 Ga-FAPI is a more effective diagnostic method for detecting distant metastases of gastric cancer than PET/ CT with 18 F-FDG. The obtained results indicate the need to use PET/CT with 68 Ga-FAPI in clinical practice for more accurate diagnosis and treatment strategy selection in gastric cancer.

  • Comparison of PET/CT with ⁶⁸Ga-FAPI-04 and ⁶⁸Ga-FAP-2286 in vivo for inflammatory and oncological diseases. Clinical cases

    by P. E. Tulin, T. A. Dengina, V. V. Solomyany, A. V. Filimonov, D. I. Nevzorov, B. I. Dolgushin

    Purpose : To study the pharmacokinetics of ⁶⁸Ga‑FAP‑2286 in oncological and inflammatory diseases and to compare the diagnostic capabilities of ⁶⁸Ga‑FAP‑2286 and ⁶⁸Ga‑FAPI‑04, including in the context of its potential use for patient selection for 177Lu‑FAP‑2286 radionuclide therapy. Material and methods : PET/CT studies with ⁶⁸Ga‑FAP‑2286 and ⁶⁸Ga‑FAPI‑04 were performed on two patients: one with an oncological disease and one with an inflammatory process. The ⁶⁸Ga‑FAP‑2286 PET/CT scan was conducted in three phases — at 5 minutes, 60 minutes, and 180 minutes after radiopharmaceutical administration, followed by an assessment of the dynamics of SUV max changes in the target regions. PET/CT scanning with ⁶⁸Ga‑FAPI‑04 was performed in a single step, 60 minutes post‑injection Conclusion : ⁶⁸Ga‑FAPI‑04 and ⁶⁸Ga‑FAP‑2286 have similar diagnostic characteristics. Differences in the pharmacokinetics of ⁶⁸Ga‑FAP‑2286 between tumorous and inflammatory changes were also identified.

  • Open Access

    The role of laparoscopic retroperitoneal lymphadenectomy in the diagnosis of gastric cancer prevalence

    by Mikael G. Abgaryan, Ekaterina I. Rusuna, Aleksei E. Kalinin, Sergei N. Berdnikov, Pavel E. Tulin, Ivan S. Stilidi, Ivan G. Avdyukhin, Авдюхин Иван Геннадьевич

    Background. Preoperative examination of affected regional and distant lymph nodes is an important prognostic criterion when choosing treatment strategies for gastric cancer. In clinical practice, computed tomography (CT) with intravenous contrast is used to determine lymph node metastases, supplemented in controversial situations by positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG). In cases of inconclusive CT and PET/CT scan results, morphological verification of the retroperitoneal lymph nodes is required using minimally invasive techniques: core biopsy and/or laparoscopy with retroperitoneal lymphadenectomy. Aim: to evaluate the informative value and safety of laparoscopic retroperitoneal lymphadenectomy for the evaluation of retroperitoneal lymph nodes suspected of gastric cancer metastases. Material and methods. A total of 482 patients diagnosed with gastric and/or cardioesophageal junction cancer type II-III according to the Siewert classification were analyzed. They were treated at the Blokhin National Medical Research Center of Oncology from 2019 to 2023. If CT revealed retroperitoneal lymph nodes suspicious for metastases, 18F-FDG PET/CT was performed. If PET/CT data clearly showed metastasis, the patient was considered inoperable (M1). If PET/CT data revealed intact retroperitoneal lymph nodes, their morphological verification was not performed. In cases of questionable metabolic changes in the retroperitoneal lymph nodes, a decision was made to morphologically verify them using core biopsy under ultrasound or CT navigation. If core biopsy was not technically feasible, laparoscopy with retroperitoneal lymphadenectomy was performed. Results. CT scans revealed retroperitoneal lymph nodes suspicious for metastases in 19/482 (3.9%) patients. 18F-FDG PET/CT scanning revealed foci of pathological radiopharmaceutical accumulation in retroperitoneal lymph nodes (M1) in 5/19 (26.3%) patients; metabolic and structural changes in the retroperitoneal lymph nodes were not detected in 6/19 (31.6%) patients. Questionable metabolic changes in the retroperitoneal lymph nodes were detected in 8/19 (52.6%) patients: core biopsy with ultrasound or CT navigation was performed in 3 (15.8%) patients, and biopsy was technically unfeasible in 5 patients. In one patient (5.3%), gastric cancer metastasis was confirmed by ultrasound-guided biopsy, and in two patients (10.5%), gastric cancer metastases were verified by retroperitoneal lymphadenectomy. No complications were recorded during core biopsy or retroperitoneal lymphadenectomy. Conclusion. Laparoscopic retroperitoneal lymphadenectomy is an informative and safe minimally invasive method for morphological verification of retroperitoneal lymph nodes suspected of containing gastric cancer metastases.

  • Open Access

    Interim Results of a Phase I/II Clinical Study to Assess the Safety And Efficacy of Peptide Receptor Radionuclide Therapy with 177Lu-DOTA-TATE Produced by the N.N. Blokhin National Medical Research Center of Oncology in Patients with Neuroendocrine Neoplasia

    by O. D. Baranova, A. S. Krylov, Yа. A. Zhulikov, E. V. Artamonova, A. A. Markovich, D. V. Likhosherstova, A. V. Filimonov, P. E. Tulin, B. I. Dolgushin, I. S. Stilidi

    Introduction : Peptide-receptor radionuclide therapy (PRRT) is currently a well-studied treatment option for patients with neuroendocrine tumors. Based on the results of the Phase III NETTER-1 and NETTER-2 trials, 177 Lu-DOTA-TATE therapy has become the standard for second- and subsequent-line therapy. However, there are currently no domestic studies investigating PRRT. In our study, we evaluated the efficacy and safety of 177 Lu-DOTA-TATE, a radiopharmaceutical drug synthesized in the cyclotron-radiochemistry laboratory of the Department of Radionuclide Diagnostics and Therapy at the N.N. Blokhin National Medical Research Center of Oncology and having undergone preclinical trials, in patients with neuroendocrine neoplasias (NENs). Materials and Methods : This phase I/II study enrolled patients with metastatic NENs of various locations with Ki-67 177 Lu-DOTA-TATE radiopharmaceutical every 8–10 weeks, along with extended-release somatostatin analogs. The primary endpoints were response rate (disease control) of ≥​​ 6 months and safety. Secondary endpoints were objective response rate, progression-free survival (PFS), and overall survival (OS). Patients were enrolled from June 2024 to July 2025. This study analyzes the Įrst 11 patients enrolled in the study. Results : Eleven patients were included in this analysis. The median age was 54 years. Primary tumor localizations: gastroenteropan‑ creatic (GEP) NEN — 6 patients (54.5 %), pheochromocytomas/paragangliomas — 3 patients (27.3 %), lung NEN and NEN metastases from the esophagus — 1 patient each (9.3 %). Median Ki-67 was 10 % (5–25 %). All patients had previously received everolimus therapy, 9 patients (81.8 %) — chemotherapy. The objective response rate (ORR) was 54.5 %, all responses were partial. Disease stabilization (DS) was recorded in 36.4 %. Disease control (DC) ≥​​ 6 months was noted in 90.9 % of cases. Median PFS and OS with a median follow-up of 11.3 months were not achieved. Grade 3–4 leukopenia was recorded in 2 patients (18.2 %). No decrease in renal function was noted. One serious adverse event associated with disease progression was recorded: pleurisy, requiring thoracentesis for fluid evacuation. Conclusion : Peptide-receptor radionuclide therapy with 177 Lu-DOTA-TATE, manufactured at the Blokhin National Medical Research Center of Oncology, resulted in high ORR and CFS rates in patients with NEN of various locations. Clinically signiĮcant myelosuppres‑ sion was observed in 18.2 % of cases.


  • Open Access

    PET/CT with 18F-BPA for various oncological diseases. The first experience of application in Russia

    by P. E. Tulin, A. A. Lipengolts, A. S. Subbotin, A. V. Filimonov, V. V. Solomyany, I. A. Nazarenko, I. A. Skripachev, D. I. Nevzorov, V. Z. Dobrokhotova, I. V. Samoylenko, et al.

    Purpose : To determine the possibilities of PET/CT with 18 F-FBFA in the diagnostics of oncological diseases. Material and methods : This prospective study included 32 patients with various verified oncological diseases. All patients underwent two consecutive PET/CT studies with two 18 F-FDG and 18 F-BPA. Two parameters were measured for 18 F-BPA: 1) Accumulation in the primary tumor and/or in metastases / recurrent tumors; 2) The tumor to normal tissue ratio (TNR). Results : Data on the physiological accumulation of 18 F-BPA were obtained (the lowest values in the brain were SUV min-max 0.45–2.99 (median 1.42), the highest values were in the oral mucosa SUV min-max 2.24–8.81 (median 4.76). Foci of pathological accumulation of 18 F-BPA corresponding to tumor tissue were identified (the highest values of accumulation of 18 F-BPA were detected in multiple myeloma — SUV max 9.59, the lowest — in nasopharyngeal plasmocytoma — SUV max 4.42). The TNR calculation made it possible to divide patients into 2 groups: TNR ≥ 2,5 (n = 15), TNR < 2,5 (n = 6), determining the potential for BNCT. Conclusion : 18 F-BPA has potential as an independent diagnostic tool. 18 F-BPA deserves attention for study as an agent that allows for differential diagnosis between tumor and non-tumor changes. The further search for the possibilities of using PET/CT with 18 F-BPA on larger cohorts of patients with various oncological diseases planned.

  • Open Access

    Lipoma in the Left Brachiocephalic Vein on 18F-PSMA PET/CT 1007: a Clinical Case

    by A. V. Parnas, A. I. Pronin, P. E. Tulin, A. V. Filimonov, V. S. Ilyakov

    Lipomas of large central veins are rare. The most common localization of these tumors is the inferior vena cava (LVA), where they are found in about 0.5 % of the general population during contrast-enhanced computed tomography (CT). Currently, no clinical cases of lipomas in the brachiocephalic vein have been published in the literature, which would have been detected during PET/CT examination. Here is a clinical case of a patient with primary multiple metachronous tumor processes: prostate cancer, breast cancer, kidney cancer, that has undergone PET/CT scan with 18F - PSMA-1007.

  • Open Access

    PET/CT with 18F-FDG in the Evaluation of Regional Metastasis of Esophageal Squamous Cell Carcinoma

    by E. S. Koroleva, P. E. Tulin, O. B. Abu-Khaidar, O. A. Konyakova, I. S. Grashchenko, V. V. Solomyany, A. V. Filimonov

    Purpose: To study the diagnostic value of PET/CT with 18F-FDG in evaluation of metastases in lymph nodes of esophageal cancer.Materials and methods: The retrospective study included 70 patients with squamous cell esophageal cancer. All patients underwent PET/CT with 18F-FDG from 2020 to 2024 in the N.N. Blokhin National Medical Research Center of Oncology. Metastases in the regional lymph nodes were-evaluated by PET/CT with 18F-FDG. Histological verification was performed in all cases.Results: PET/CT with 18F-FDG demonstrated sensitivity 86 % and specificity 78 % of visualization of metastases in the regional lymph nodes.Conclusion: PET/CT with 18F-FDG is a promising imaging method in evaluation of cancer extent squamous cell esophageal carcinoma, detecting metastases in unchanged lymph nodes. PET/CT limitations require a comprehensive diagnostic approach.


  • Open Access

    Comparative Analysis of PET/CT with 68Ga-FAPI and 18F-FDG in the Diagnosis of Esophageal Cancer.

    by E. S. Koroleva, P. E. Tulin, O. Abu-Khaidar, A. А. Urtenova, I. A. Skripachev, V. V. Solomyany, A. V. Filimonov

    Purpose: To study the diagnostic value of PET/CT with 68Ga-FAPI compared with 18F-FDG in evaluation of cancer extent of esophageal. Materials and methods: The study included 15 patients (10 men, 5 women) with esophageal cancer. All patients underwent PET/CT with 18F-FDG and ⁶⁸Ga-FAPI-04 from January to December 2024. Primary tumor, metastases in regional lymph nodes were evaluated by PET/CT with ⁶⁸Ga-FAPI-04 and 18F-FDG. Histological verification was performed in all cases. Results: PET/CT with ⁶⁸Ga-FAPI-04 demonstrated high level of visualization of metastases in regional lymph nodes. The method finds a little more metastasis in regional lymph nodes in comparison with PET/CT with 18F-FDG. Conclusion: PET/CT c ⁶⁸GA-FAPI-04 demonstrates promising results in evaluation of cancer extent of esophageal. Further studies on large cohorts of patients are necessary to clarify the role of PET/CT with FAPI-04 for various histological types of esophageal cancer.

  • Open Access

    PET/CT with 68Ga-FAPI and 18F-FDG in the Detection of Metastases in Regional Lymph Nodes in Gastric Cancer

    by E. V. Belkin, P. E. Tulin, O. B. Abu-Khaydar, I. A. Skripachev, A. V. Filimonov

    Purpose: To determine the diagnostic effectiveness of PET/CT with 68Ga-FAPI in gastric cancer.Matreial and Methods:The study included 42 patients with histologically confirmed gastric cancer. All patients underwent PET/CT with 68Ga-FAPI and PET/CT with 18F-FDG. The diagnostic accuracy of the methods was compared based on sensitivity and specificity parameters in detecting metastatic involvement of regional lymph nodes. Data assessment was conducted based on histologically verified disease and clinical follow-up data.Results: PET/CT with 68Ga-FAPI is a more effective diagnostic method for detecting metastases in regional lymph nodes compared to PET/CT with 18F-FDG. Our results support the clinical potential of PET/CT with 68Ga-FAPI for improved diagnosis and treatment planning in gastric cancer.


  • Open Access

    18F-metafluorobenzylguanidine (18F-MFBG) PET/CT in Neuroblastoma. The First experience In Russia: Comparison with 123I-metaiodobenzylguanidine (123I-MIBG) Scintigraphy

    by A. S. Krylov, A. A. Odzharova, P. E. Tulin, M. V. Rubanskaya, D. I. Nevzorov, N. I. Nesterova

    Neuroblastoma is the most frequent extracranial solid tumor of childhood. In 7 out of 10 cases, neuroblastoma is already disseminated at the time of diagnosis. Of the current nuclear medicine techniques, scintigraphy with methaiodobenzylguanidine, which is a 123I-labeled noradrenaline analog or (123I-MIBG), plays the most important role in the evaluation of neuroblastoma. Currently, a new PET-tracer, 18F-MFBG (18F-labeled benziguanidine analog), has emerged that can be used in the radionuclide diagnosis of neuroblastomas. Our clinical observations showed identical diagnostic efficiency to scintigraphy data with 123I-MIBG with significantly faster blood clearance than 123I-MIBG, which allows us to perform studies as early as 1 h after intravenous administration. In one case PET/CT with 18F-MIBG revealed additional tumor foci, which allowed to correct therapy, which is certainly of great importance in clinical practice.